Premium
Successful cell‐mediated cytokine‐activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation
Author(s) -
Gesundheit Benjamin,
Shapira Michael Y.,
Resnick Igor B.,
Amar Avraham,
Kristt Don,
Dray Lilianne,
Budowski Einat,
Or Reuven
Publication year - 2009
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21346
Subject(s) - medicine , myeloid leukemia , immunotherapy , hematopoietic stem cell transplantation , donor lymphocyte infusion , transplantation , stem cell , immunology , leukemia , myeloid , haematopoiesis , cytokine , oncology , immune system , biology , genetics
Acute myeloid leukemia (AML) is an extremely aggressive disease with a high relapse rate even after allogeneic hematopoietic stem cell transplantation (HSCT). We report the successful outcome of cell‐mediated cytokine‐activated immunotherapy in a high‐risk pediatric AML patient who relapsed shortly after allogeneic HSCT. Donor lymphocyte infusion along with interferon induced a graft‐versus‐leukemia effect, presenting as a reversible episode of graft‐versus‐host disease, which led to stable complete donor chimerism and total eradication of AML for over 24 months, at the time of this report. The curative potential of immunotherapy in hematological malignancies is discussed. Am. J. Hematol., 2009. © 2008 Wiley‐Liss, Inc.